New study: HRT may boost GLP-1 weight loss results — what Canadian patients should know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A retrospective cohort study of nearly 3,900 midlife women, presented October 20, 2026, at the Menopause Society Annual Meeting in San Diego, found that hormone therapy was associated with significantly greater and sustained weight loss among women taking semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for weight management), though the same statistically significant benefit did not hold for tirzepatide (sold in Canada as Mounjaro for diabetes; its weight-management formulation, Zepbound, is FDA-approved in the US but has not received Health Canada authorization as of this writing). For Canadian women navigating both menopause and weight concerns, the study raises a clinically plausible but still unconfirmed question: does estrogen make GLP-1 medications work better?

The study enrolled women over 45 with a body mass index above 27 kg/m2, roughly 2,400 on semaglutide and 1,500 on tirzepatide. Those also using hormone therapy lost more weight on semaglutide, and the signal held across a larger independent cohort than earlier, smaller studies had examined. Lead author Dr. Regina Castaneda of Mayo Clinic Florida described the findings as "a consistent signal" while being direct about the limits: "It is too early to draw firm conclusions. These findings need to be confirmed in adequately designed prospective trials, and it's important to remember that weight loss is not an indication for menopause hormone therapy."

What this means in Canada

Semaglutide as a weight-management therapy (Wegovy, Novo Nordisk) received Health Canada authorization in 2021. Coverage varies sharply by province. As of 2026, Ontario's OHIP does not cover Wegovy for obesity; Quebec's RAMQ covers semaglutide only under specific metabolic criteria; British Columbia's PharmaCare and Alberta's AHCIP have similarly narrow criteria tied to comorbidities like type 2 diabetes or cardiovascular disease. Patients paying out of pocket face costs of roughly CAD $350 to $500 per month for Wegovy, depending on dose and pharmacy. Tirzepatide (Mounjaro) is Health Canada-authorized for type 2 diabetes but not yet for obesity as a standalone indication in Canada.

Hormone therapy products such as estradiol (sold in Canada as Estrace in oral form and Estradot as a transdermal patch, among others) are covered under most provincial drug plans when prescribed for menopausal symptoms, though formulary details differ. The Society of Obstetricians and Gynaecologists of Canada (SOGC) supports hormone therapy for managing vasomotor symptoms and other menopausal concerns in appropriate candidates, but the SOGC has not issued a position statement specifically on combining hormone therapy with GLP-1 medications for weight management. Health Canada has not issued guidance on this combination.

Canadian telehealth platforms including Cleo (a Canadian women's-health platform), Felix, Maple, and Telus Health offer GLP-1 prescribing services, and some, including Science and Humans (scienceandhumans.com), offer both hormone therapy and metabolic care. None of these platforms should be treated as a substitute for a specialist consultation, particularly for patients managing both menopause and obesity.

What changed

Previous evidence on this question came from small retrospective studies. This new analysis is described by the Menopause Society as the first large real-world cohort to examine the interaction between hormone therapy and GLP-1 response in midlife women. The cohort size, nearly 4,000 participants, gives the semaglutide finding more statistical weight than earlier signals, though the study design is still observational and retrospective, meaning causation cannot be established.

The biological rationale is not new. Preclinical research has suggested a potential synergistic effect between estrogen and GLP-1 receptor signaling, meaning the two systems may amplify each other's activity in ways that affect appetite regulation and fat metabolism. The fact that the effect appeared stronger with semaglutide (a pure GLP-1 receptor agonist) than with tirzepatide (which also activates the glucose-dependent insulinotropic polypeptide receptor) is itself a finding worth noting. It suggests the interaction, if real, may be specific to GLP-1 signaling rather than a general metabolic effect of weight-loss drugs.

Dr. Stephanie Faubion, medical director for the Menopause Society, said the study "highlights the importance of considering menopause-specific factors when developing personalized approaches to weight management for midlife women."

What Canadian patients should know

If you are a midlife woman currently taking or considering a GLP-1 medication, this study does not change prescribing guidelines. Hormone therapy is approved in Canada for menopausal symptoms, not for weight loss, and that remains true after this study. A clinician who suggests starting hormone therapy solely to improve GLP-1 response would be acting outside current evidence.

That said, if you are already a candidate for hormone therapy based on menopausal symptoms and are also using semaglutide, this study gives your prescriber one more data point to factor into a shared decision. The two treatments are not contraindicated together, and many Canadian women are already using both.

Provincial coverage gaps matter here. If you are paying out of pocket for Wegovy and your province does not cover it, adding hormone therapy does not change that cost equation. Patients in provinces with broader pharmacare coverage, or those enrolled in private drug plans, should check their formulary for both drug classes.

If you are considering a telehealth option, confirm that the platform operates in your province and is staffed by Canadian-licensed physicians or nurse practitioners. US-based platforms such as Midi Health and Hone Health do not serve Canadian patients.

Limitations and open questions

This is a retrospective observational study. Women who chose hormone therapy may differ from those who did not in ways the researchers could not fully control for, including baseline health, socioeconomic status, or access to specialist care. The study has not yet been published in a peer-reviewed journal; it was presented at a conference, which means it has not completed full external peer review.

The tirzepatide finding did not reach statistical significance, which means the data do not support concluding that hormone therapy improves tirzepatide outcomes. The researchers themselves flagged this as deserving further study.

Health Canada has not reviewed or commented on these findings. The SOGC has not issued guidance. Prospective randomized trials, the standard needed to establish causation, have not been completed. Until that evidence exists, this study is hypothesis-generating, not practice-changing.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.